Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Synthesis and Regulation of Thyroid Hormones01:20

Synthesis and Regulation of Thyroid Hormones

Low blood levels of the thyroid hormones — triiodothyronine (T3) and thyroxine (T4) — signal the hypothalamus to release the thyrotropin-releasing hormone (TRH). TRH then reaches the pituitary gland and stimulates the release of thyroid-stimulating hormone(TSH) into the bloodstream.
Upon reaching the thyroid gland, TSH stimulates the follicular cells' active uptake of iodide ions from the blood. The ions diffuse to the apical surface of the cells and are oxidized to iodine. The iodine is then...
Hyperthyroidism I: Introduction01:25

Hyperthyroidism I: Introduction

Hyperthyroidism is a type of thyrotoxicosis characterized by the thyroid gland's overproduction of the thyroid hormones triiodothyronine (T3) and thyroxine (T4). This hormone excess increases the basal metabolic rate and enhances sensitivity to catecholamines.DiagnosisDiagnosis is based on clinical features and biochemical testing. It typically shows suppressed thyroid-stimulating hormone (TSH) levels below 0.4 mIU/L, with elevated free T3 and/or T4. Additional tests, including thyroid...
Graves Disease II: Pathophysiology01:24

Graves Disease II: Pathophysiology

Graves’ disease is an autoimmune disorder characterized by the production of thyroid-stimulating immunoglobulins (TSI) that activate TSH receptors, leading to excessive synthesis and release of thyroid hormones (T3 and T4) and resulting in hyperthyroidism.Among all causes of hyperthyroidism, Graves’ disease is the most common and can happen at any age, though it is more frequent in women. It produces a hypermetabolic state with features such as weight loss, tachycardia, tremor, and heat...
Hyperthyroidism II: Pathophysiology01:27

Hyperthyroidism II: Pathophysiology

Hyperthyroidism is a hypermetabolic state caused by elevated levels of thyroid hormones, triiodothyronine (T3) and thyroxine (T4). It results from dysregulation at the thyroid, pituitary, or immune system level and affects multiple organ systems.PathophysiologyThe most common cause of hyperthyroidism is Graves’ disease, an autoimmune disorder in which antibodies, specifically thyroid-stimulating antibodies (TSAb), a subtype of TSH receptor antibodies (TRAb), bind to and activate TSH receptors...
Hypothyroidism II: Pathophysiology01:23

Hypothyroidism II: Pathophysiology

Hypothyroidism is a disorder characterized by insufficient production of thyroid hormones, which regulate metabolism, energy balance, and multiple organ systems.TypesHypothyroidism is classified based on the level of dysfunction. Primary hypothyroidism results from intrinsic thyroid gland dysfunction, causing reduced hormone production despite normal or increased stimulation. Secondary hypothyroidism arises from inadequate thyroid-stimulating hormone (TSH) secretion by the pituitary. Tertiary...
Graves' Disease I: Introduction01:28

Graves' Disease I: Introduction

Graves' disease is an autoimmune disorder that causes hyperthyroidism, or overactivity of the thyroid gland. It results from autoantibodies called thyroid-stimulating immunoglobulins (TSIs), which bind to thyroid-stimulating hormone (TSH) receptors, leading to overstimulation of hormone production and a hypermetabolic state.EtiologyAlthough considered idiopathic, Graves’ disease has well-established contributing factors. There is a strong genetic component, with increased prevalence in...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Effect of a Prior Two-Hour Postural Test on Seated Saline Suppression Test Results in Patients Predominantly Evaluated for Adrenal Incidentalomas.

Journal of clinical medicine·2026
Same author

Prevention of fatty acid-induced maladaptation in secretin tumor cell-1 enteroendocrine cells by allicin, a transient receptor potential ankyrin 1 agonist.

The Journal of pharmacology and experimental therapeutics·2025
Same author

An impact of type 2 diabetes mellitus on NKT-like cell population in humans: a new insight into impaired immune response in hyperglycemia.

Frontiers in endocrinology·2025
Same author

Editorial: Progress in diagnosis and treatment of hypothalamic & pituitary disorders.

Frontiers in endocrinology·2025
Same author

The Prevalence of Reduced Bone Mineral Density and the Impact of Specific Auxological Factors and Hormones on Bone Mass in Children with Endocrine Disorders.

Journal of clinical medicine·2025
Same author

Management strategies for optimal linear growth in Noonan syndrome (NS) children: minireview and case series of three patients with NS due to PTPN11 mutation and confirmed growth hormone deficiency.

Endokrynologia Polska·2025
Same journal

Single-cell RNA sequencing in thyroid cancer: a methodological review and thyroid specific dissociation protocol.

Thyroid research·2026
Same journal

Quality of life in hypothyroid subjects treated with levothyroxine: a cross-sectional study.

Thyroid research·2026
Same journal

Cancer-associated fibroblasts in thyroid cancer stroma correlate with tumour progression and desmoplasia: a histopathological study.

Thyroid research·2026
Same journal

Effect of social determinants of health care on outcomes for well-differentiated thyroid cancer at an urban safety-net hospital.

Thyroid research·2026
Same journal

Panel-negative strategy for suspected fusion-driven papillary thyroid carcinoma.

Thyroid research·2026
Same journal

Time to euthyroidism and its predictors among thyrotoxicosis patients on antithyroid drugs at tertiary hospitals, Western Oromia, Ethiopia: a retrospective cohort study.

Thyroid research·2026
See all related articles

Related Experiment Video

Updated: May 16, 2026

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice
07:02

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice

Published on: August 23, 2019

Successful treatment of thyrotoxicosis is accompanied by a decrease in serum sclerostin levels.

Elżbieta Skowrońska-Jóźwiak1, Kinga Krawczyk-Rusiecka, Krzysztof C Lewandowski

  • 1Department of Endocrinology and Metabolic Diseases, Polish Mother's Memorial Hospital - Research Institute, Rzgowska St, No, 281/289, 93-338, Lodz, Poland. alewin@csk.umed.lodz.pl.

Thyroid Research
|November 14, 2012
PubMed
Summary
This summary is machine-generated.

Thyrotoxicosis treatment significantly lowers sclerostin levels in patients. This study investigated the impact of thyroid hormone levels on sclerostin, a key regulator of bone formation.

Related Experiment Videos

Last Updated: May 16, 2026

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice
07:02

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice

Published on: August 23, 2019

Area of Science:

  • Endocrinology
  • Bone Metabolism
  • Molecular Biology

Background:

  • Sclerostin, produced by osteocytes, inhibits bone formation.
  • Hormonal regulation of sclerostin is known for PTH and glucocorticosteroids.
  • The effect of thyroid hormones on sclerostin has not been previously studied.

Purpose of the Study:

  • To investigate the influence of thyroid hormones on sclerostin synthesis.
  • To evaluate serum sclerostin concentrations in thyrotoxicosis patients before and after treatment.

Main Methods:

  • 15 patients with thyrotoxicosis were studied.
  • Serum sclerostin, free T3, and free T4 levels were measured before and after 6-10 weeks of thiamazole treatment.
  • Statistical analysis included descriptive statistics, Mann-Whitney U test, and Spearman's correlation coefficient.

Main Results:

  • Thyrotoxicosis treatment led to significant decreases in free T3 and free T4 levels.
  • Serum sclerostin concentrations also significantly decreased post-treatment.
  • No correlation was found between sclerostin levels and serum FT3 or FT4 concentrations.

Conclusions:

  • Achieving a euthyroid state significantly reduces serum sclerostin levels.
  • This reduction may indicate a decrease in bone metabolism.
  • Further research is needed to explore a potential direct influence of thyroid hormones on the SOST gene.